Nivestym Drug Interactions: What to Avoid and What to Tell Your Doctor

Nivestym (filgrastim-aafi) is a powerful biologic medication that interacts with several other drugs in clinically important ways. Before starting Nivestym, it's essential to tell your oncologist and pharmacist about everything you take — including prescription medications, over-the-counter drugs, supplements, and herbal products.

This guide covers the most important Nivestym drug interactions, what to watch for, and the critical timing rule that every patient on chemotherapy must follow.

The #1 Rule: The 24-Hour Chemotherapy Window

Do not administer Nivestym within 24 hours before or after cytotoxic chemotherapy. This is the most critical safety rule for Nivestym.

Here's why: chemotherapy kills rapidly dividing cells, including bone marrow stem cells. If you take Nivestym close to chemotherapy, the stimulated stem cells may be more vulnerable to chemotherapy-induced damage — potentially worsening myelosuppression. The standard practice is to start Nivestym at least 24 hours after the last chemo dose and stop it at least 24 hours before the next scheduled chemo dose.

Interaction 1: Pegfilgrastim (Neulasta, Udenyca, and other biosimilars)

Filgrastim (the active component of Nivestym) and pegfilgrastim (Neulasta) are very similar medications — pegfilgrastim is simply a longer-acting, pegylated form of filgrastim. Using both at the same time is generally not recommended and provides no additional benefit while potentially causing additive side effects, including excessive white blood cell production (leukocytosis) and more pronounced bone pain.

Your doctor will prescribe either Nivestym or a pegfilgrastim product — not both simultaneously.

Interaction 2: Lithium

Lithium (used for bipolar disorder and other psychiatric conditions) can potentiate the release of neutrophils from the bone marrow. When taken together with Nivestym, this can lead to an exaggerated rise in white blood cell counts — a condition called leukocytosis (WBC count above 100,000/mm³).

This interaction requires closer monitoring of blood counts. If you take lithium for a psychiatric condition, be sure to tell your oncologist before starting Nivestym so they can plan appropriate CBC monitoring.

Interaction 3: Other G-CSF and GM-CSF Agents

Using Nivestym together with other colony-stimulating factors — such as sargramostim (Leukine, a GM-CSF agent) — is not recommended. Combining G-CSF and GM-CSF products can lead to unpredictable white blood cell counts and is generally avoided in clinical practice. Most insurance prior authorization policies also explicitly prohibit concurrent use of G-CSF and GM-CSF.

Interaction 4: Bleomycin

Bleomycin is a chemotherapy drug associated with pulmonary toxicity (lung damage). While there is no direct pharmacokinetic interaction with filgrastim, some case reports suggest that G-CSF use may be associated with increased pulmonary complications in patients also receiving bleomycin-containing regimens. Discuss this with your oncologist if your chemotherapy includes bleomycin.

Effect on Lab Tests: Bone Imaging

Nivestym can interfere with bone imaging tests (such as bone scans/scintigraphy). Because Nivestym dramatically increases bone marrow activity, a bone scan performed during Nivestym therapy may show increased uptake in bone marrow areas — which could be misinterpreted as abnormal. If you need a bone scan or PET scan during Nivestym therapy, inform both your oncologist and the radiologist so they can account for this in their interpretation.

Monitoring: Blood Count Testing During Nivestym Therapy

While not technically a "drug interaction," it's worth noting that regular CBC monitoring is required during Nivestym therapy. Specifically:

• CBC with differential should be obtained twice weekly during Nivestym therapy for chemotherapy patients
• If WBC rises above 100,000/mm³ during PBPC mobilization, Nivestym should be discontinued
• Platelet counts should be monitored — thrombocytopenia (low platelets) has been reported with Nivestym use

What to Tell Your Doctor Before Starting Nivestym

Before your first Nivestym dose, tell your oncologist if you:

• Take lithium for a psychiatric condition
• Are prescribed any other white blood cell growth factors (pegfilgrastim, sargramostim, etc.)
• Have sickle cell disease or trait — Nivestym can trigger severe sickle cell crises
• Have a history of serious allergic reactions to filgrastim or pegfilgrastim products
• Are pregnant, planning to become pregnant, or breastfeeding
• Have any kidney problems (glomerulonephritis has been associated with filgrastim use)
• Have a scheduled bone scan or PET scan — Nivestym can affect imaging results

The Bottom Line

The most critical interaction to remember: never take Nivestym within 24 hours of chemotherapy on either side. Beyond that, the key interactions involve pegfilgrastim, lithium, and the effect on bone imaging. Keep your full medication list updated and share it with every member of your care team. For more on Nivestym safety, see our guide on Nivestym side effects. And if you need help locating your Nivestym prescription, medfinder can check pharmacies near you.